EverSource Wealth Advisors LLC Buys 156 Shares of Illumina, Inc. (NASDAQ:ILMN)

EverSource Wealth Advisors LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 16.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,108 shares of the life sciences company’s stock after purchasing an additional 156 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Illumina were worth $148,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in ILMN. Bleakley Financial Group LLC acquired a new position in Illumina during the fourth quarter worth $751,000. Zacks Investment Management bought a new position in shares of Illumina in the 3rd quarter valued at about $2,924,000. Van ECK Associates Corp increased its stake in shares of Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock worth $20,347,000 after purchasing an additional 22,718 shares during the last quarter. Strategic Financial Concepts LLC bought a new stake in shares of Illumina in the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP lifted its stake in Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after purchasing an additional 6,263 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 0.1 %

ILMN opened at $85.68 on Tuesday. The stock has a market capitalization of $13.57 billion, a price-to-earnings ratio of -11.16, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a twelve month low of $80.18 and a twelve month high of $156.66. The company has a 50-day simple moving average of $112.46 and a 200 day simple moving average of $129.53.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have weighed in on ILMN. Royal Bank of Canada lowered their price target on Illumina from $247.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 12th. HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a report on Friday, February 28th. Piper Sandler raised their price target on Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Barclays reiterated an “underweight” rating on shares of Illumina in a report on Tuesday, March 11th. Finally, Citigroup cut their target price on shares of Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.